Corporal fat distribution and lipidic and glicemic profiles of HIV-infected patients;Distribuição da gordura corporal e perfis lipídico e glicêmico de pacientes infectados pelo HIV

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 51, Issue 1, 2007, Pages 42-51

  Guimarães, Milena Maria Moreira ^a,b   Greco, Dirceu Bartolomeu ^a   De O Jr , Antônio Ribeiro ^a   Penido, Mariana Guimarães ^a   Machado, Lucas José De C ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b NONE   (Brazil)

Author keywords

Antiretroviral therapy; HIV; Lipodystrophy; Lipodystrophy syndrome HIV; Metabolic syndrome HIV; Side effect

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ABDOMINAL SUBCUTANEOUS FAT; ADULT; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; CHEMICALLY INDUCED DISORDER; CROSS-SECTIONAL STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAABDOMINAL FAT; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD GLUCOSE; BODY FAT DISTRIBUTION; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INTRA-ABDOMINAL FAT; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; STATISTICS, NONPARAMETRIC; SUBCUTANEOUS FAT, ABDOMINAL;

EID: 34247172190     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302007000100008     Document Type: Article

References (42)

1. Miller KD, Jones E, Yanovski JA, Shankar R, Feurstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998;35:871-5.
2. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hiperlipidemia, insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:51-8.
3. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Int Med 1997;127:947.
4. Viraben R, Aquilina C. Indinavir associated lipodystrophy. AIDS 1998;12:37-9.
5. Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 2004;170(2):229-38.
6. Grundy SM, Brewer HB, Cleeman JI, Smith SC, L'Enfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
7. Hogg RS, O'Shaughnessy MV, Gataric N, Yip B, Craib K, Svhechter MT, et al. Decline in deaths from Aids due to new antiretrovirals (letter). Lancet 1997;349:1294.
8. Palella FJ Jr, Delaney KM, Moornan AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining of morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Eng J Med 1998;338:853-60.
9. Marins JRP, Jamal LF, Chen SY, Barros MB, Hudes ES, Barbosa AA, et al. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS 2003;17:1675-82.
10. Radominski RB, Hebroso DP, Cerri GG, Halpern A. O uso da ultra-sonografia na avaliação da distribuição de gordura abdominal. Arq Bras Endocrinol Metab 2000;44:5-12.
11. Durnin JVGA, Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16-72 years. Brit J Nutr 1974;32:77-97.
12. Lukaski HC. Methods for the assessment of human body composition: traditional and new. Am J Clin Nutr 1987;46:537-56.
13. Armellini F, Zamboni M, Robbi R, Tudesco T, Rigo L, Bergamo-Andreis IA, et al. Total and intra abdominal fat measurements by ultrasound and computerized tomography. Inter J Obes 1983;17:209-14.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985;28:412-9.
15. MINISTÉRIO DA SAÚDE. Recomendações para terapia anti-retroviral em adultos e adolescentes infectados pelo HIV, 2001.
16. Heath KV, Hogg RS, Chan KJ, Harris M, Montessori V, O'Shaughnessy, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV-AIDS treatment database. AIDS 2001;15:231-9.
17. Carr A, Samaras S, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-9.
18. Yanovski JA, Miller KD, Kino T, Friedman TC, Chrousos GP, Tsigos C, et al. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 1999;84:1925-31.
19. Kotler DP, Thea DM, Heo M, Allison, DB, Engelson ES, Wang J, et al. Relative influences of sex, race, environment, and HIV infection on body composition in adults. Am J Clin Nutr 1999;69:432-9.
20. Kotler DP, Rosenbaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr 1999;20:228-37.
21. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13:1659-67.
22. Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000;14:37-49.
23. Deprés JP. Lipoprotein metabolism in abdominal obesity. Prog Obes Res J 1990;285-90.
24. Wannamethee SG, Shaper AG, Morris RW. Measures of adiposity in the identification of metabolic abnormalities in elderly men. Am J Clin Nutr 2005;81:1313-21.
25. Wei M, Gaskill SP, Haffner SM, Stern MP. Waist circumference as the best predictor of noninsulin dependent diabetes mellitus compared to body mass index, waist hip ratio and other anthropometric measurements in Mexican-Americans. Obes Res 1997;5:16-23.
26. Martínez E, Bianchi L, García-Viejo MA, Bru C, Gatell JM. Sonographic assessment of regional fat in HIV1-infected people. Lancet 2000;356:1412-3.
27. Lean MEJ, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. Brit Med J 1995;311:158-161.
28. Leite CC, Matsuda D, Wajchenberg BL, Cerri GG, Halpern A. Correlação da medida de espessura intra-abdominal medida pela ultra-sonografia com os fatores de risco cardiovascular. Arq Bras Endocrinol Metab 2000;44:49-56.
29. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia and lipodystrophy - a 5-year cohort study. Arch Intern Med 2000;160(13):2050-6.
30. Heath K, Chan KJ, Singer J, O'Shaughnessey MV, Montanes JS, Hogg RS. Incidence of morphological and lipid abnormalities: Gender and treatment differentials after initiation of first antiretroviral therapy. Inter J Epidemiol 2002;31:1016-20.
31. Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, Weller IV. Lipodystrophy in patients naïve to HIV protease inhibitors (correspondence) AIDS 1999;13(6):735-7.
32. Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Eng J Med 1992;327:329-37.
33. Caramelli B, Bernoche CSM, Sartori MC, Sposito AC, Santos RD, Monachini MC, et al. Hiperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. Braz J Infec Dis 2001;5:332-8.
34. Walli R, Herfort O, Michl GM, Demant T, Jäger H, Dieterle C, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998;12:F167-73.
35. Ledru E, Christeff N, Patey O, Truchis P, Melchior JC, Gougeon ML. Alteration of tumor necrosis factor-α T-cell homeostasis following potent antiretroviral therapy; contribution to the development of human immunodeciciency virus-associated lipodystrophy syndrome. Blood 2000;95:3191-8.
36. Depairon M, Chessex S, Sudre P, Rodondi N, Doser N, Chave JP, et al. Premature atherosclerosis in HIV-infected individuals-focus on protease inhibitor therapy. AIDS 2001;15:329-34.
37. Berthold HK, Parhofer KG, Ritter MM, Addo M, Wasmuth JC, Schliefer K, et al. Influence of protease inhibitor therapy on lipoprotein metabolism. J Inter Med 1999;246:567-75.
38. Hadigan C, Corcovan C, Stanley T, Piecuch S, Klibanski A, Grinspoon S. Fasting hiperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J Clin Endocrinol Metab 2000;85:35-41.
39. Lumpkin M. FDA Public Health Advisory: Reports of diabetes and hyperglycemia in patients receiving proteae inhibitors for the treatment of human immunodeficiency virus (HIV). Washington, DC: US Government Printing Office, 1997.
40. Lee ECC, Walmsley S, Fantus IG. New onset diabetes mellitus associated with protease inhibitors therapy in an HIV-positive patient: case report and review. CMAF 1999;161:161-4.
41. Dube MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 2000;31:1467-75.
42. Mulligan K, Grunfeld DC, Tai VW, Algren H, Pang M, Chernoff DN, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23:3543.